Currency Traders Week Ahead  In the US, inflation figures and JOLTs job openings will be in the spotlight.

FOREX INVESTORS BUZZ Weekly Forex Update

FOREX INVESTORS BUZZ Weekly Forex Update

CURRENCY TRADERS

Weekly Forex Update Last week, the forex market was dictated by dovish minutes of the Federal Reserve’s <span data-recalc-dims=(Fed) and the European Central Bank’s July monetary policy meeting." width="300" height="132" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/06/weekly-forex-buzz-word.png?resize=300%2C132&ssl=1 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/06/weekly-forex-buzz-word.png?w=733&ssl=1 733w" sizes="(max-width: 300px) 100vw, 300px" />

Weekly Forex Update Last week, the forex market was dictated by dovish minutes of the Federal Reserve’s (Fed) and the European Central Bank’s July monetary policy meeting.

The greenback ended mixed against its key peers last week, after minutes of the Fed’s latest meeting indicated that the central bank could demur on additional interest rate hike this year. According to minutes, policymakers appeared divided over another interest rate increase this year as some members opposed further hikes until there was more concrete evidence that the recent softness in inflation is transitory. However, others argued that such a delay could cause an eventual overshooting in inflation.

On the macro front, advance retail sales in the US posted its sharpest increase in 7 months in July, suggesting that consumer spending was off to a good start in the third quarter. Moreover, confidence amongst Americans surged to a 7-month high in August. Further, the nation’s business inventories jumped to a 7-month high in June, while the NAHB housing market index recorded an unexpected rise in August. Additionally, the number of Americans filing for initial jobless claims dropped to a 6-month low in the week ended 12 August. Also, the nation’s industrial production climbed less-than-expected in July. On the contrary, manufacturing production recorded an unexpected drop in July.

The Euro ended the week lower against the USD, after minutes of the ECB’s July meeting revealed that policymakers expressed concerns over stubbornly low inflation. Further, officials remained wary over the strength in the Euro and warned that the recent surge in the currency could hamper the central bank’s efforts to get inflation to its target.

The Pound ended the week on a weaker footing against the USD, after annual inflation in Britain came in softer-then-expected in July. On the contrary, the nation’s ILO unemployment rate unexpectedly dropped in the three months to June, highlighting robust jobs market despite an overall slowdown in economic growth



Weekly Forex Update

 

EURUSD Forex Exchange Weekly Outlook

EURUSD

Last week, the EUR traded 0.51% lower against the USD and closed at 1.1761, after minutes of the ECB’s July meeting highlighted some nervousness among committee members about the strength in the Euro. On the macro front, second estimate of the Eurozone’s seasonally adjusted gross domestic product (GDP) advanced 0.6% on a quarterly basis in the second quarter of 2017, confirming the preliminary print. Further, the region’s final consumer price index (CPI) rose 1.3% on an annual basis in July, in line with the flash estimate, while seasonally adjusted trade surplus expanded more-than-anticipated in June. On the contrary, the region’s seasonally adjusted industrial production eased more-than-expected in June, while seasonally adjusted current account surplus sharply narrowed in the same month. Moreover, the region’s seasonally adjusted construction output declined in June. Separately, Germany’s seasonally adjusted GDP advanced less-than-expected by 0.6% on a quarterly basis in the second quarter of 2017. The EUR hit a high of 1.1838 and a low of 1.1662 against the USD in the previous week. The pair is expected to find its first support at 1.1669 and first resistance at 1.1845. The second support is expected at 1.1577 and second resistance at 1.1929. This week, investors will focus on the Markit manufacturing and services PMIs as well as the ZEW economic sentiment data across the Eurozone. Additionally, the Eurozone’s consumer confidence coupled with Germany’s Ifo expectations index, would also be keenly watched by traders.

 GBPUSD FOREX EXCHANGE Weekly Outlook August 21, 2017

GBPUSD

During the previous week, the GBP traded 1.11% lower against the USD and ended at 1.2870, following the release of weaker-than-expected inflation data in the UK. Data indicated that Britain’s consumer price index (CPI) climbed less-than-anticipated by 2.6% on an annual basis in July. Nevertheless, the nation’s retail sales topped market consensus in July. Moreover, the nation’s ILO unemployment rate unexpectedly dropped in the three months to June, while annual average earnings including bonus climbed above market expectations in the same period. The GBP hit a high of 1.3022 and a low of 1.2832 against the USD in the previous week. The pair is expected to find its first support at 1.2796 and first resistance at 1.2986. The second support is expected at 1.2719 and second resistance at 1.3099. Investors will keep a close watch on Britain’s 2Q GDP report, BBA mortgage approvals and public sector net borrowing data, all slated to release this week.

 USDJPY FOREX EXCHANGE Weekly Outlook

USDJPY

The USD traded marginally lower against the JPY last week, with the pair closing at 109.18. Macroeconomic data revealed that Japan’s preliminary GDP expanded higher-than-expected by 1.0% on a quarterly basis in the second quarter of 2017, while the nation’s final industrial production was revised higher in June. Additionally, the nation’s adjusted merchandise trade surplus widened more-than-anticipated in July. The pair traded at a high of 110.95 and a low of 108.60 during the previous week. Immediate downside, the first support level is seen at 108.22, followed by 107.24, while on the upside, the first resistance level situated in 110.57, followed by 111.94. This week, traders will focus on Japan’s national consumer price index and flash Nikkei manufacturing PMI data.

 USDCHF FOREX EXCHANGE Weekly Outlook

USDCHF

The USD traded 0.29% higher against the CHF last week, with the pair closing at 0.9646. On the data front, Switzerland’s producer and import price index remained flat on a monthly basis in July, at par with market expectations. The USD hit a high of 0.9766 and a low of 0.9586 against the CHF in the previous week. Immediate downside, the first support level is seen at 0.9567, followed by 0.9487, while on the upside, the first resistance level situated in 0.9747, followed by 0.9847. Going forward, Switzerland’s trade balance and industrial production data, set to release this week, will attract a lot of investor attention.

 USDCAD FX EXCHANGE Weekly Outlook August 21, 2017

USDCAD

During the previous week, the USD traded 0.73% lower against the CAD and ended at 1.2585. The Canadian dollar rose against the USD, after Canada’s consumer price index advanced 1.2% on an annual basis in July, meeting market expectations. Moreover, the nation’s Teranet/National Bank house price index climbed in July. On the other hand, existing home sales eased in July, while manufacturing shipments sharply fell in June. During the previous week, the pair traded at a high of 1.2778 and a low of 1.2557. The pair is expected to witness its first support at 1.2502 and second support at 1.2419, while the first resistance is expected at 1.2723 and second resistance at 1.2861. Looking ahead, traders will closely monitor Canada’s retail sales data, the sole important release this week.

 AUDUSD FX Exchange Weekly Outlook

AUDUSD

Last week, the AUD traded 0.44% higher against the USD and closed at 0.7929, on the back of hawkish minutes of the Reserve Bank of Australia’s (RBA) August meeting. Minutes indicated that officials expressed confidence that Australian economic growth is likely to pick up pace in the coming months. However, the central bank reiterated its view that the housing market as well as household debt warrants “careful monitoring” and that any further rise in the local currency could lead to slower growth and subdued inflation. Gains in Aussie were boosted further, after data showed that Australia’s seasonally adjusted unemployment rate fell to 5.6% in July, in line with market expectations. Also, the nation’s Westpac leading index rebounded in July. The AUD hit a high of 0.7963 and a low of 0.7808 against the USD in the previous week. The pair is expected to witness its first support at 0.7838 and second support at 0.7745, while the first resistance is expected at 0.7993 and second resistance at 0.8055. With no major economic releases in Australia this week, investor sentiment will be governed by global macroeconomic events.

 

Gold

Gold fell last week, closing 0.4% lower at USD1284.13 per ounce, as fading concerns of a possible war between the US and North Korea increased risk appetite among investors. Gold hit a high of USD1306.90 per ounce and a low of USD1272.70 per ounce during the previous week. The yellow metal is expected to witness its first support at USD1273.03 per ounce and second support at USD1255.77 per ounce, while the first resistance is expected at USD1307.23 per ounce and second resistance at USD1324.17 per ounce.

 CRUDE OIL FUTURES – WEEKLY OUTLOOK: AUGUST 21 – 25

 

Crude Oil

Crude oil traded 0.63% lower in the previous week, closing at USD48.51 per barrel, after the Energy Information Administration (EIA) reported that US crude production jumped by 79,000 barrels per day (bpd) to 9.502 million bpd in the week ended 11 August, hitting its highest level in over 2 years. However, losses in crude prices were limited, after the EIA reported that US crude oil stockpiles declined by 8.95 million barrels to 466.50 million barrels in the week ended 11 August, while the American Petroleum Institute (API) indicated a massive draw of 9.20 million barrels in the US crude oil inventories in the same week. The commodity hit a high of USD49.16 per barrel and a low of USD46.46 per barrel in the previous week. Immediate downside, the first support level is seen at USD47.07 per barrel, followed by USD45.42 per barrel, while on the upside, the first resistance level situated in USD49.77 per barrel, followed by USD50.82 per barrel.

 

Like up on FACEBOOK




logo



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD) (USDCNY)



BUZ INVESTORS PRESS RELEASE Scorpion Grow Lights Future Farm Technologies Inc. (the “Company” or “Future Farm”) ( OTCQB : FFRMF ) is pleased to announce that it is sold out of its exclusive line of Scorpion LED COB Grow Lights

Future Farm Announces California Update

Future Farm Announces California Update



BUZ INVESTORS PRESS RELEASE Scorpion Grow Lights Future Farm Technologies Inc. (the “Company” or “Future Farm”) ( OTCQB : FFRMF ) is pleased to announce that it is sold out of its exclusive line of Scorpion LED COB Grow Lights

PRESS RELEASE Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) ( OTCQB: FFRMF) is pleased to announce that its subsidiary, FFM Consulting Services, LLC, is making progress in California with respect to the management services being provided to the Huntington Park extraction facility and the Riverside County cultivation facility.

Since installation of the extraction equipment at the Huntington Park facility, the team has been scaling up production and dialing in operations using various strains and types of solvents to produce high quality extraction distillates. To date, the team has acquired over 250-lbs of high quality trim material of both THC and distinct CBD strains from various organic producers located in Northern California. All of the acquired trim material is of high quality and fully tested to ensure that it is free of pesticides and microbiological contamination. This week, the team extracted the first CBD batch using organic grape alcohol resulting in a highly pure, potent, and effective medicinal product. This CBD product is suitable for patients seeking therapeutic relief from their symptoms without incurring the “high” associated with THC containing extracts.

The Company is working toward completing multiple purchase orders for its whole flower and extracted oil products that are expected to be completed in early September.



Future Farm

The Riverside County cultivation facility is progressing as well and the team will be harvesting during the end of August. The Company will be able to use this first harvest to execute a side-by-side comparison of its own LED grow lights versus the standard High Pressure Sodium (HPS) lights. The HPS lights are currently consuming 1000 watts per light whereas the Company’s LED Canada grow lights are utilizing 550 watts per light. The Company expects to use data from the harvest to better understand the savings potential per kilowatt-hour over the lifecycle of each plant.

“We are eagerly anticipating the harvest data from the cultivation facility and expect to yield in excess of 1.5-lbs per light. In addition, the extraction operations are developing well and we expect to soon provide our investors with revenue production. We have been working closely with potential customers to understand their needs to ensure that we provide them with the high-quality product that they expect. We are adjusting operations real-time to ensure we can provide them with consistent supply for ongoing long-term contracts,” says Mr. John Sweeney, Future Farm’s COO.

For further information, contact William Gildea, Director, at 617.834.9467.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, CEO & Chairman

About Future Farm

The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability .

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com which caters to B2B customers is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

 

 

Like up on FACEBOOK


bitcoin card

logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD Provides an Update on Harvest by Acreage Pharms Ltd.

Invictus MD Provides an Update on Harvest by Acreage Pharms Ltd.

 

 

Invictus MD AnINVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company"is pleased to announce that its wholly nounces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

PRESS RELEASE INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that its wholly owned subsidiary, Acreage Pharms Ltd. (“Acreage Pharms”), a licensed producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), completed its first two successful harvests earlier this month.  Acreage Pharms, utilizing its pesticide free growing systems, anticipates two harvests to take place the first week of September.

Trevor Dixon, CEO of Acreage Pharms commented “The yields from both of the first two harvests exceeded expectations. The additional two harvests in the first week of September will utilize the entire grow space which will maximize yields and generate sufficient data to determine anticipated annual production rates. Acreage Pharms will be in a position to receive the license to sell once the QA team has analyzed the results of the third-party lab tests. This will be a significant milestone for Acreage Pharms.”

The initial harvests in this purpose built, state-of-the-art production facility along with the highly capable, cultivation team that uses Good Production Practices, has resulted in high quality, non-irradiated medical cannabis.



INVICTUS MD STRATEGIES

The company is also pleased to report that Phase 2, a 27,800 square foot purpose built, multiple room production facility, is well under construction with scheduled completion by the end of January 2018.  Given the production improvements realized from Phase 1, the new facility is projected to produce up to 4,200 kgs per annum.  That represents a 800% increase in production over the existing production facility.  The capital costs of constructing the Phase 2 production facility is within the $6 million that was initially budgeted.

Dan Kriznic, Chairman & CEO, Invictus MD  commented “Invictus MD is well capitalized for expansion with approximately $28.5 million in cash and is prepared for an exciting year of growth. We have one of the industry’s most experienced teams and our focus remains on building our shareholder value with significant expansion plans as the demand for cannabis increases.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the Canadian cannabis sector, namely the Licensed Producers under the ACMPR, being its wholly owned subsidiary Acreage Pharms and its non-wholly owned affiliate AB Laboratories Inc.; along with Fertilizer and Nutrients through its non-wholly owned subsidiary Future Harvest Development Ltd.

For more information, please visit www.invictus-md.com.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Oil prices edged lower on Wednesday, as investors looked ahead to weekly data from the U.S. on stockpiles of crude and refined products.

OIL ON THE BACK FOOT AHEAD OF US SUPPLY UPDATE

OIL ON THE BACK FOOT AHEAD OF US SUPPLY UPDATE

Oil prices edged lower on Wednesday, as investors looked ahead to weekly data from the U.S. on stockpiles of crude and refined products.

Oil prices edged lower on Wednesday, as investors looked ahead to weekly data from the U.S. on stockpiles of crude and refined products.

The U.S. West Texas Intermediate crude September contract was at $49.12 a barrel by 3:35AM ET (0735GMT), down 5 cents, or around 0.1%.

Elsewhere, Brent oil for October delivery on the ICE Futures Exchange in London shed 12 cents, or 0.2%, to $52.02 a barrel.

Oil prices fell for a second straight session in volatile trade on Tuesday.

The U.S. Energy Information Administration will release its official weekly oil supplies report at 10:30AM ET (1430GMT).



Oil prices edged

Analysts expect crude oil inventories dropped by around 2.7 million barrels at the end of last week, while gasoline supplies are seen decreasing by about 1.4 million barrels and distillates are forecast to fall about 131,000 barrels.

After markets closed Tuesday, the American Petroleum Institute said that U.S. oil inventories fell by 7.89 million barrels in the week ended August 4.

The API report also showed a gain of 1.5 million barrels in gasoline stocks, while distillate stocks fell by 157,000 barrels.

There are often sharp divergences between the API estimates and the official figures from EIA.

Meanwhile, officials from a joint OPEC and non-OPEC technical committee said on Tuesday that they expect greater compliance with their output-cutting pact.

According to recent calculations, compliance fell to 86% in July, the lowest level since January.

OPEC and 10 producers outside the cartel, including Russia, agreed since the start of the year to slash 1.8 million barrels per day in supply until March 2018 in order to reduce a global supply glut and rebalance the market.

However, so far, the deal has had little impact on global inventory levels due to rising supply from producers not participating in the accord, such as Libya and Nigeria, as well as a relentless increase in U.S. shale output.

Elsewhere on Nymex, gasoline futures for September was little changed at $1.602 a gallon, while September heating oil ticked down 0.8 cents to $1.620 a gallon.

Natural gas futures for September delivery shed half a cent to $2.818 per million British thermal units.

Like up on FACEBOOK


logo



COMMODITIES: (CRUDE OIL) (SILVER) (GOLD)



GT Biopharma OXIS  Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith

GT Biopharma OXIS Announces Corporate Update Conference Call

GT Biopharma Inc. (OXIS) Announces Corporate Update Conference Call

GT Biopharma OXIS  Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith

PRESS RELEASE GT Biopharma OXIS  Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith and Chairman Anthony Cataldo
GT Biopharma Inc. (OTCQB:OXIS and Euronext Paris OXI.PA), a targeted immunotherapies company with incoming close to market treatments (GTP acquisition) for Central Nervous System diseases (nurology and pain), will hold a conference call, hosted by www.biotechstocks.com, to discuss the upcoming merger of Georgetown Translation Pharmaceuticals, Inc. (GTP) and advancements made with the targeted immunotherapies currently in FDA clinical trials.
“The merger of GT Biopharma, Inc. (Oxis) and GTP will greatly accelerate the clinical development of exciting new treatments to meet the medical needs of those suffering from cancer and neurologic diseases,” said Dr. Clarence-Smith.

“The additions of the GTP pipeline and CEO Dr. Kathleen Clarence-Smith along with our new incoming CMO (formerly Chief Medical Officer, Oncology at Pfizer, Inc. (NYSE:PFE), will be instrumental in completing GT Biopharma/Oxis FDA phase 2 clinical trial and advance the highly sought after TriKE oncology platform technology from Dr. Jeff Miller of the University Of Minnesota Masonic Cancer Clinic.



GT Biopharma OXIS

Additionally, we are very excited with the incoming GTP product pipeline, which adds significant value with the fast pathway of central nervous system products as they continue to move towards commercial license.”

GT Biopharma Chairman and CEO Tony Cataldo stated, “There is a lot going on inside GT Biopharma (Oxis) and it is better to speak with our shareholders and market participants so everyone can understand what all of the excitement is about. Kathleen and I are pleased to make ourselves available to discuss the rationale of this merger.”

Shareholders and interested parties are invited to participate in the conference call hosted by www.biotechstocks.com. The call will start promptly at 4:15pm EST on Wednesday, August 16, 2017. The dial in number for the call is 712-775-7031. Meeting ID number is 576-591-822.

About GT Biopharma, Inc.: GT Biopharma, Inc (formerly known as Oxis International, Inc.) is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. Oxis’ lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug’s cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-3550 TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. As demonstrated in non-clinical models, this targeted immunotherapy directs immune cells to kill cancer cells while diminishing drug-related toxicity.

About GTP Inc.: GTP is a privately-owned biotechnology company focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for CNS disease (Neurology and Pain) and shepherding the products through the FDA approval process to the NDA. GTP products currently include treatment for neuropathic pain, refractory epilepsies, the symptoms of myasthenia gravis, and motion sickness.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



 Cannabix Technologies Inc. eveloper of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace,

Cannabix Technologies Develops Beta 3.0 Marijuana Breathalyzer and Provides Update

Cannabix Technologies Develops Beta 3.0 Marijuana Breathalyzer and Provides Update

 

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety

 

 Cannabix Technologies Inc. eveloper of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace,

FOREX INVESTORS BUZZ  PRESS RELEASE  Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to announce that it has developed a “Beta 3.0” (Cannabix Marijuana Breathalyzer) device based on its FAIMS- (field asymmetric waveform ion mobility spectrometry) technology with major advances in the design and commercial capabilities of the device.  The Beta 3.0 will include a conventional rechargeable battery, improved ion flow, the latest pulse driver chips to improve resolution and sensitivity. The new design includes improvements that will allow for dynamic testing and for easier configurability that will be needed for more demanding test/user environments.

The Beta 3.0 device will also include a specialized flow-through heat exchanger technology that stabilizes breath temperature in cold as well as humid temperature settings and allows for breath testing in all temperature conditions. The new device includes improved dielectric barrier discharge ionization source and high-voltage square wave generator which has been given superior voltage shielding. The Beta 3.0 device incorporates real time breath analysis for concentrations of O2, CO2, humidity, temperature and flow-rate which will allow for key metrics for real-time detection of delta-9-tetrahydrocannabinol (“THC”) in human breath.



Cannabix Technologies

 

Testing update and Establishment of British Columbia Testing Laboratory

Cannabix has been developing its FAIMS based Cannabix Marijuana Breathalyzer for the detection of THC through exhaled breath and continues testing its devices in British Columbia and Florida for sensitivity and consistency of results for Evidential Breath testing purposes.

Recent testing with the Cannabix Marijuana Breathalyzer Beta 2.0 prototype device with human subjects after smoking THC cigarettes demonstrated the successful identification of THC in relation to the subject’s background matrix in real-time. (THC being the psychoactive component of marijuana).  In addition to THC, several metabolites were identified in the breath of the human subjects including 11-hydroxy-delta-9-tetrahydrocannabinol and delta-9-carboxy-tetrahydrocannabinol, the results were confirmed by mass spectrometry after the inhalation of cannabis.

The Company has substantially increased its testing capabilities with investment in a state-of-the art lab space in Vancouver, B.C., purchase of Thermo Scientific mass spectrometer and related equipment.  Cannabix has also added to its technical team with the addition of Dr. David Hasman who is an expert in the field of toxicology and forensic science as well the operation of mass spectrometer based testing devices.

Furthermore, the Company is in discussions to collaborate, using the Cannabix Marijuana Breathalyzer, with a significant U.S. based institution with large user group and enhanced testing environment.

About Cannabix Technologies Inc

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update

 

FOREX INVESSTORS  PRESS RELEASE  Acreage Pharms Ltd   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that its licensed production facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), Acreage Pharms Ltd. (“Acreage Pharms”) located near Edson, Alberta, utilizing a multi-room indoor perpetual growing methodology, will begin its first harvest the first week of August, with the second harvest occurring the following week.  The company anticipates a harvest to take place approximately monthly going forward.

Invictus MD is further pleased to announce that Acreage Pharms has received its development permit for Phase 2 and has broken ground initiating construction on its 27,800 square foot purpose built, multiple room production facility. All contractors and suppliers necessary for the project have been scheduled. Invictus MD has committed to investing $6.0 million, which will be used to fund the costs of constructing the production facility.

“Following our successful harvest at the AB Laboratories production facility as announced earlier, and by securing the development permit for our Alberta production facility, with $30 million cash available and the majority earmarked for building production capacity, Invictus MD is prepared for an exciting year of growth,” said Dan Kriznic, Executive Chairman and CEO, Invictus MD. “Led by one of the industry’s most experienced teams, we are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, our large land package allows for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy, and further establishing our leadership position as Canada’s cannabis company” added Kriznic.



Acreage Pharms Ltd

Invictus MD also announced that Mr Paul Sparkes and Mr. Josef W. Hocher have been appointed to the Company’s Board of Directors.

Mr. Paul Sparkes is an accomplished business leader with over twenty five years’ experience in media, public affairs, venture capital, and Canada’s political arena. He is Currently President of Otterbury Holdings Inc., a corporation advising growth companies in the private and public markets.  Most recently Mr. Sparkes was Executive Vice Chair, Director and co-founder of Difference Capital Financial, a TSX-listed specialty finance company. Previously, Mr. Sparkes was Executive Vice President, Corporate Affairs for CTVglobemedia (now Bellmedia). Prior to joining Bell Globemedia in 2001 as Group Vice-President, Public Affairs, Mr. Sparkes held senior positions in public service, including with the Government of Canada and the Government of Newfoundland and Labrador. From 1996 to 2001, he served in the Office of the Prime Minister of Canada as Director of Operations, and Special Assistant for Atlantic Canada. Mr. Sparkes also served as Executive Assistant to two Premiers of Newfoundland and Labrador. Mr. Sparkes sits on several public and private boards including Thunderbird Entertainment (private), Bluedrop Performance Learning Inc. (TSXV: BPL), Antler Gold Inc (TSXV:ANTL.V) BlastGard International Inc (BLGA-US) and is a former board member of the Liquor Control Board of Ontario ( LCBO).

Mr. Josef W. Hocher was a founder of Buried Hill Energy, an international oil and gas company, where he acted as co-chief executive in creating, developing and implementing the organization’s strategic direction.  He continues to serve as the Senior Independent Director and is also either a Chair or a member of various committees. Mr. Hocher also founded Hitic Energy Ltd., and was a partner at Osler, Hoskin & Harcourt LLP. He currently serves as Chairman of Orthoshop Geomatics Ltd., a geomatics services company; holds the position of Chief Commercial Officer at Field Upgrading Limited and Western Hydrogen Limited and since 2016, has been a Partner at Cassels, Brock & Blackwell LLP.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR, including its wholly owned subsidiary Acreage Pharms Ltd., as well as its investment in the fully licensed facility AB Laboratories Inc.; and Fertilizer and Nutrients through Future Harvest Development Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Executive Chairman & CEO

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward Looking Information includes, but is not limited to, disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action; and the plans for completion of the Offering, expected use of proceeds and business objectives. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “anticipates”, “expects”, “understanding”, “has agreed to” or variations of such words and phrases or statements that certain actions, events or results “would”, “occur” or “be achieved”. Although Invictus has attempted to identify important factors that could affect Invictus and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended, including, without limitation, the risks and uncertainties related to the Offering not being completed in the event that the conditions precedent thereto are not satisfied. In making the forward-looking statements in this news release, Invictus has applied several material assumptions, including the assumptions that (1) the conditions precedent to completion of the Offering will be fulfilled so as to permit the Offering to be completed on or about June 1, 2017; (2) all necessary approvals will be obtained in a timely manner and on acceptable terms; and (3) general business and economic conditions will not change in a materially adverse manner. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Invictus does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



mCig Announces 5 Million Reduction in Shares Outstanding

mCig, Inc., (MCIG ) Provides Shareholder Update on Corporate Developments

|Chart | Calendar   | TRADE NOW | mCig 

MCIG Provides Shareholder Update on Corporate Developments

 

BUZ INVESTORS PRESS RELEASE Provides Shareholder Update  mCig, Inc., ( OTCQB : MCIG ), a leading distributor of innovative products, technologies, and services for the global medical cannabis industry provides shareholders with a recap of FY2017 highlights, successes and FY2018 outlook and expansion.
Key Highlights of FY2017:

Net Sales increased to $4.5 million, a 158% increase year to year comparison, and a 1,294% increase for the 4th quarter compared to same period last fiscal year
Net income of $1.5 million compared to a $1.4 million loss from the previous year, and an increase of $2.9 million net earnings
Cash and cash equivalents of $1.6 million compared to $0.1 million from the previous year (a 1,369% increase), and a 400% increase from last quarter. mCig generated $2.1 million in cash from operating activities
mCig assets increased to $6.8 million, having 6 times more assets than it does liabilities
MCIG has established 4 targets for FY2018 in which to measure its performance. Our collective strategy aims to:



Provides Shareholder Update

Take Aggressive steps to increase revenues and profits.
Reach 1 million active combined customers across all MCIG segments.
Spin-off one subsidiary into a publicly traded company, offering a share dividend to all MCIG shareholders.
Strategically enable company to conduct business in diversified sectors, both inside and out of the cannabis industry.
GROW CONTRACTORS

Grow Contractors (GC) was MCIG’s fastest and largest growing segment in FY2017. GC generated more than $1.1 million in working capital for MCIG in FY2017.

GC has successfully completed its first two contracts, Sin City and Green Leaf Farms. GC’s talent and ability to consult and construct, has made our partners capable of meeting deadlines for “fast-track” recreational licenses. Both partners have received their official State Certificate of Occupancy to allow them to begin growing cannabis. GC continues to consult for both groups and is working on hiring and building added partnership opportunities in addition to construction. Solaris and Forest Grove projects are full steam ahead and expected to finish Phase I by September. GC also completed various smaller projects in Washington and Oregon in FY2017.

While GC has expanded operations outside of Nevada, Nevada continues to remain its focal point state, and will continue to be in FY2018. With recreational cannabis sales starting in Las Vegas on July 1, 2017, the entire market is abuzz with energy. GC has received more requests for grow consultations in the last 2 months than it has in the past two years. Projects continue to line up as demand remains increasingly strong. With 45 million tourists, higher discretionary spending, and being able to purchase cannabis with the simple requirement of being 21 years of age, Nevada is expected to top Colorado revenues and historical growth patterns. With the growth potential of the recreational cannabis market emerging in Nevada, GC is well positioned for construction and consulting services in the state of Nevada for many years to come.

MCIG will continue to update the market and shareholders of GC ‘s progress through social media (Instagram, Facebook), and our websites (growcontractors.com, mciggroup.com). We believe GC has an early adopter advantage and large growth potential in Nevada, which positions the company for facility management opportunities and owning our own profitable grow in future.

CANNABIZ SUPPLY

MCIG continues to develop and strengthen its cannabis supply venture, Cannabiz Supply. The revenue for this division (100% owned by MCIG), continues to double month over month. The business has grown in various areas — selling state mandated and custom packaging, office, dispensary supplies, and vape products. The company has gained multiple accounts with distribution to every dispensary, major grower, and production facility in the state of Nevada.

MCIG will continue to foster and grow this division, and once established and perfected in Nevada, the company plans to expand into a national cannabis supply and distribution company. “The growth of the cannabis industry is unparalleled to anything I have seen in my 45 years in business,” states Cannabis Supply, CEO, Charles Fox, “and Cannabiz Supply is poised to be a major player in the packaging and supply side every step of the way.”

GIGESOFT

In April 2017 MCIG launched 420cloud.com, a mobile application available on both Android and Apple devices. A web browsable version of 420 Cloud is planned for release in the next 3 months. During the forecasted period, new areas of the application will be released and will expand on user connectivity, user experience, premium features, microtransactions, payment wallet, advertising network, additional websites connected through the app menu and expansion to user shopping through the 420 Tienda marketplace.

MCIG considers this project to be long term and ongoing, that will produce strong intellectual property and assets, while continuing to build and enhance our cannabis job listings, weedistry 420 news, cannabis social media, and more. Owning our own tech platform opens many opportunities for future growth.

Business Description

Industry: Tobacco Products » Tobacco    NAICS: 312230    SIC: 2111
Compare: NYSE:(AOI,) OTCPK:(BXNG), OTCPK:(GLLA), OTCPK:(VPRB), OTCPK:(SRUP), OTCPK:(NHLE), OTCPK:(VAPI), OTCPK:(RCGR), NYSE:(TPB), NYSE:(UVV), NYSE:(VGR), OTCPK:(SWMAF), OTCPK:(GGNPF), OTCPK:(IMBBY), OTCPK:(JAPAF), NYSE:(RAI,) AMEX:(BTI), NYSE:(MO), NYSE:(PM) » details
Traded in other countries: M06.Germany,
Headquarter Location: USA

mCig Inc is a technology company. It is engaged in manufacturing and retailing of loose-leaf Ecig.

mCig Inc was incorporated in the State of Nevada on December 30, 2010 originally under the name Lifetech Industries, Inc. Effective August 2, 2013, the name was changed from Lifetech Industries, Inc. to mCig, Inc. The Company manufactures and retails the mCig, an affordable loose-leaf eCig. It provides a smoking experience by heating plant material, waxes, and oils delivering, in the Company’s opinion, a smoother inhalation experience. It operates in two two long-term secular trends: The decriminalization and legalization of marijuana for medicinal or recreational purposes – legalizing medicinal and recreational marijuana usage is steadily on the rise not only domestically but also internationally, The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”), as smokers move away from traditional cigarettes onto e-cigarettes. Smoking tobacco causes numerous health problems, including disease and death. It competes with other sellers of electronic cigarettes, notably Lorillard, Inc., Altria Group, Inc. and Reynolds American Inc.
Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Executive Chairman Provides a Corporate Update

Invictus MD’s Executive Chairman Provides a Corporate Update

Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

BUZ INVESTORS  Corporate Update  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) Canada’s Cannabis Company, is pleased to provide a corporate update on the back of its recently closed bought deal financing, and reprises its vision to expand and solidify its cultivation portfolio.

“Following our successful financing with Canaccord Genuity Corp., Eventus Capital Corp., Echelon Wealth Partners Inc., GMP Securities L.P. and PI Financial Corp., including the over-allotment option, for aggregate gross proceeds of $25,008,750, Invictus MD is well capitalized and prepared for an exciting year of growth,” said Dan Kriznic, Executive Chairman, Invictus MD. “Led by one of the industry’s most experienced teams, we are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, we now have the largest land package in Canada for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy,” added Kriznic.

Corporate Update

“When its management team visited TSX Venture Exchange (TSXV) on May 5, 2017 and opened the trading day, we shared that celebration with all those who have contributed to our success – especially our team, the board, advisers and investors,” said Kriznic.  “From our early beginnings three years ago, we had a clear goal and the desire to do something remarkable within this budding marketplace.  We have always taken pride in knowing we’re working towards becoming a source of uncompromising quality of medical cannabis and to be ready for the future new recreational market upon legalization.”

In early May, AB Ventures Inc. (“AB Ventures”), an incorporated company formed to develop a second licensed expansion facility through its common ownership with AB Laboratories Inc. (“AB Labs”) a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) which maintains a 16,000 square foot facility located near Hamilton, Ontario, closed its 100-acre land acquisition and once licensed under the ACMPR, will be used for future cannabis cultivation.  To facilitate the construction of the initial 42,000 square foot cultivation facilities, with plans to construct additional production facilities on the new land totaling 100,000 square feet, Mr. Michael Alezane has been appointed construction manager.  Considering the magnitude of AB Ventures’ land holdings and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, we will have the capacity for significant growth to keep pace with the growing medical and future recreational demand.

AB Labs, which has achieved full production capacity, recently conducted its first harvest with very favorable results and will shortly apply for its pre-sales inspection.

“The Company is focused on achieving increased production profile growth in the near future.  Cultivation began earlier in the month at Acreage Pharms Ltd. (Acreage Pharms), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”),” stated Trevor Dixon, President and CEO of Invictus MD. “Planning has begun for the Phase 2 build out; Acreage Pharms has an existing 6,800 square foot production facility with an expansion plan floor plate of 27,400 square feet, that sits on 150 acres of land in West Central Alberta. To facilitate the construction of Phase 2, Mr. Harmen Bangma has been appointed construction manager.” Alberta has low cost of production as a result of low energy and water costs and provides the capability to construct facilities to meet the demand that the coming adult recreational marijuana use will create. Acreage Pharms also has plans to produce extracted or oil based products oils are rapidly gaining market share in the marijuana sector.

Invictus MD’s wholly owned venture into consumer cannabis devices; Poda Technologies Ltd. (“Poda”), is set imminently for a spin out.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp., Canada’s Cannabis Company, is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including investment in the fully licensed facilities operated by AB Laboratories Inc. and Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

Business Description

Industry: Asset Management » Asset Management    NAICS: 523999    SIC: 7299
Compare: OTCPK:(HGBL), OTCPK:(WISH), OTCPK:(PRDGF), OTCPK:(AABVF), AMEX:(RCG), NAS:(RAND), OTCPK:(GRNBF), AMEX:(NPN), OTCPK:(LDHL), AMEX:(MIW), OTCPK:(INNO), NAS:(XRDC), NAS:(GROW), OTCPK:(HALN), AMEX:(NJV), AMEX:(MAB), OTCPK:(HGHRF), AMEX:(EMI), NYSE:(MTR), AMEX:(GRF) » details
Traded in other countries: IMH.Canada, 8IS1.Germany,
Headquarter Location: Canada

Invictus MD Strategies Corp is engaged in the investment, acquisition and development of synergistic businesses in an effort to increase and sustain growth and value.

 

 

Like up on FACEBOOK

 


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )